|
1
|
Estimated Incidence, Mortality and
Prevalence Worldwide in 2012. //globocaniarc.fr/Pages/fact_sheets_cancer.aspx.
Accessed Mar 27, 2014
|
|
2
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wilson WR and Hay MP: Targeting hypoxia in
cancer therapy. Nature reviews Cancer. 11:393–410. 2011. View Article : Google Scholar
|
|
4
|
Brahimi-Horn MC, Chiche J and Pouyssegur
J: Hypoxia and cancer. J Mol Med. 85:1301–1307. 2007. View Article : Google Scholar
|
|
5
|
Zhang H, Okamoto M, Panzhinskiy E, Zawada
WM and Das M: PKC delta/midkine pathway drives hypoxia-induced
proliferation and differentiation of human lung epithelial cells.
Am J Physiol Cell Physiol. 306:C648–C658. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vaporidi K, Tsatsanis C, Georgopoulos D
and Tsichlis PN: Effects of hypoxia and hypercapnia on surfactant
protein expression proliferation and apoptosis in A549 alveolar
epithelial cells. Life Sci. 78:284–293. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zagzag D, Zhong H, Scalzitti JM, Laughner
E, Simons JW and Semenza GL: Expression of hypoxia-inducible factor
1alpha in brain tumors: association with angiogenesis, invasion,
and progression. Cancer. 88:2606–2618. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Volm M and Koomagi R: Hypoxia-inducible
factor (HIF-1) and its relationship to apoptosis and proliferation
in lung cancer. Anticancer Res. 20:1527–1533. 2000.PubMed/NCBI
|
|
9
|
Wang Q, Li LH, Gao GD, et al: HIF-1alpha
up-regulates NDRG1 expression through binding to NDRG1 promoter,
leading to proliferation of lung cancer A549 cells. Mol Biol Rep.
40:3723–3729. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luo F, Liu X, Yan N, et al:
Hypoxia-inducible transcription factor-1alpha promotes
hypoxia-induced A549 apoptosis via a mechanism that involves the
glycolysis pathway. BMC Cancer. 6:262006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chi JT, Wang Z, Nuyten DS, et al: Gene
expression programs in response to hypoxia: cell type specificity
and prognostic significance in human cancers. PLoS Med. 3:e472006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim WY and Kaelin WG: Role of VHL gene
mutation in human cancer. J Clin Oncol. 22:4991–5004. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sermeus A and Michiels C: Reciprocal
influence of the p53 and the hypoxic pathways. Cell Death Dis.
2:e1642011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee SJ, No YR, Dang DT, et al: Regulation
of hypoxia-inducible factor 1alpha (HIF-1alpha) by lysophosphatidic
acid is dependent on interplay between p53 and Kruppel-like factor
5. J Biol Chem. 288:25244–25253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park SY, Jeong KJ, Lee J, et al: Hypoxia
enhances LPA-induced HIF-1alpha and VEGF expression: their
inhibition by resveratrol. Cancer Lett. 258:63–69. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schumpelick VH-PB and Schackert HK:
Chirurgisches Forum und DGAV Forum. Springer; Berlin: 2009
|
|
17
|
Meyer SE, Hasenstein JR, Baktula A, et al:
Kruppel-like factor 5 is not required for K-RasG12D lung
tumorigenesis, but represses ABCG2 expression and is associated
with better disease-specific survival. Am J Pathol. 177:1503–1513.
2010. View Article : Google Scholar
|
|
18
|
Tong D, Czerwenka K, Heinze G, et al:
Expression of KLF5 is a prognostic factor for disease-free survival
and overall survival in patients with breast cancer. Clin Cancer
Res. 12:2442–2448. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Budihardjo I, Oliver H, Lutter M, Luo X
and Wang X: Biochemical pathways of caspase activation during
apoptosis. Annu Rev Cell Dev Biol. 15:269–290. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nature reviews Cancer. 2:38–47. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Graves EE, Maity A and Le QT: The tumor
microenvironment in non-small-cell lung cancer. Semin Rad Oncol.
20:156–163. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cui J, Mao X, Olman V, Hastings PJ and Xu
Y: Hypoxia and miscoupling between reduced energy efficiency and
signaling to cell proliferation drive cancer to grow increasingly
faster. J Mol Cell Biol. 4:174–176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bruick RK: Oxygen sensing in the hypoxic
response pathway: regulation of the hypoxia-inducible transcription
factor. Genes Dev. 17:2614–2623. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lenihan CR and Taylor CT: The impact of
hypoxia on cell death pathways. Biochem Soc Trans. 41:657–663.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu Y, Liu J and Huang H: Recent agents
targeting HIF-1alpha for cancer therapy. J Cell Biochem.
114:498–509. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Diakiw SM, D’Andrea RJ and Brown AL: The
double life of KLF5: opposing roles in regulation of
gene-expression, cellular function, and transformation. IUBMB Life.
65:999–1011. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nandan MO, Chanchevalap S, Dalton WB and
Yang VW: Kruppel-like factor 5 promotes mitosis by activating the
cyclin B1/Cdc2 complex during oncogenic Ras-mediated
transformation. FEBS Lett. 579:4757–4762. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reed JC: Dysregulation of apoptosis in
cancer. J Clin Oncol. 17:2941–2953. 1999.PubMed/NCBI
|
|
30
|
Ghavami S, Hashemi M, Ande SR, et al:
Apoptosis and cancer: mutations within caspase genes. J Med Genet.
46:497–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Krepela E, Dankova P, Moravcikova E, et
al: Increased expression of inhibitor of apoptosis proteins,
survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol.
35:1449–1462. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu N, Gu L, Findley HW, et al: KLF5
interacts with p53 in regulating survivin expression in acute
lymphoblastic leukemia. J Biol Chem. 281:14711–14718. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yun YJ, Li SH, Cho YS, Park JW and Chun
YS: Survivin mediates prostate cell protection by HIF-1alpha
against zinc toxicity. Prostate. 70:1179–1188. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Van Hoecke M, Prigent-Tessier AS, Garnier
PE, et al: Evidence of HIF-1 functional binding activity to
caspase-3 promoter after photothrombotic cerebral ischemia. Mol
Cell Neurosci. 34:40–47. 2007.PubMed/NCBI
|
|
35
|
Majumder PK, Febbo PG, Bikoff R, et al:
mTOR inhibition reverses Akt-dependent prostate intraepithelial
neoplasia through regulation of apoptotic and HIF-1-dependent
pathways. Nat Med. 10:594–601. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhong H, Chiles K, Feldser D, et al:
Modulation of hypoxia-inducible factor 1alpha expression by the
epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP
pathway in human prostate cancer cells: implications for tumor
angiogenesis and therapeutics. Cancer Res. 60:1541–1545. 2000.
|
|
37
|
Park JH, Lee JY, Shin DH, Jang KS, Kim HJ
and Kong G: Loss of Mel-18 induces tumor angiogenesis through
enhancing the activity and expression of HIF-1alpha mediated by the
PTEN/PI3K/Akt pathway. Oncogene. 30:4578–4589. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang M, Ma Q, Hu H, et al: Stem cell
factor/c-kit signaling enhances invasion of pancreatic cancer cells
via HIF-1alpha under normoxic condition. Cancer Lett. 303:108–117.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sodhi A, Montaner S, Patel V, et al: The
Kaposi’s sarcoma-associated herpes virus G protein-coupled receptor
up-regulates vascular endothelial growth factor expression and
secretion through mitogen-activated protein kinase and p38 pathways
acting on hypoxia-inducible factor 1alpha. Cancer Res.
60:4873–4880. 2000.
|
|
40
|
Fukuda R, Hirota K, Fan F, Jung YD, Ellis
LM and Semenza GL: Insulin-like growth factor 1 induces
hypoxia-inducible factor 1-mediated vascular endothelial growth
factor expression, which is dependent on MAP kinase and
phosphatidylinositol 3-kinase signaling in colon cancer cells. J
Biol Chem. 277:38205–38211. 2002. View Article : Google Scholar
|
|
41
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
|
|
42
|
Zundel W, Schindler C, Haas-Kogan D, et
al: Loss of PTEN facilitates HIF-1-mediated gene expression. Genes
Dev. 14:391–396. 2000.PubMed/NCBI
|
|
43
|
Liu R, Zheng HQ, Zhou Z, Dong JT and Chen
C: KLF5 promotes breast cell survival partially through fibroblast
growth factor-binding protein 1-pERK-mediated dual specificity
MKP-1 protein phosphorylation and stabilization. J Biol Chem.
284:16791–16798. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Schofield CJ and Ratcliffe PJ: Oxygen
sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 5:343–354.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Forsythe JA, Jiang BH, Iyer NV, et al:
Activation of vascular endothelial growth factor gene transcription
by hypoxia-inducible factor 1. Mol Cell Biol. 16:4604–4613.
1996.PubMed/NCBI
|
|
46
|
Melillo G, Musso T, Sica A, Taylor LS, Cox
GW and Varesio L: A hypoxia-responsive element mediates a novel
pathway of activation of the inducible nitric oxide synthase
promoter. J Exp Med. 182:1683–1693. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Feldser D, Agani F, Iyer NV, Pak B,
Ferreira G and Semenza GL: Reciprocal positive regulation of
hypoxia-inducible factor 1alpha and insulin-like growth factor 2.
Cancer Res. 59:3915–3918. 1999.PubMed/NCBI
|
|
48
|
Lofstedt T, Jogi A, Sigvardsson M, et al:
Induction of ID2 expression by hypoxia-inducible factor-1: a role
in dedifferentiation of hypoxic neuroblastoma cells. J Biol Chem.
279:39223–39231. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yee Koh M, Spivak-Kroizman TR and Powis G:
HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci.
33:526–534. 2008.PubMed/NCBI
|
|
50
|
Zou C, Yu S, Xu Z, et al: ERRalpha
augments HIF-1 signalling by directly interacting with HIF-1alpha
in normoxic and hypoxic prostate cancer cells. J Pathol. 233:61–73.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jung JE, Kim HS, Lee CS, et al: STAT3
inhibits the degradation of HIF-1alpha by pVHL-mediated
ubiquitination. Exp Mol Med. 40:479–485. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Minet E, Mottet D, Michel G, et al:
Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90
interaction. FEBS Lett. 460:251–256. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ohh M, Park CW, Ivan M, et al:
Ubiquitination of hypoxia-inducible factor requires direct binding
to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol.
2:423–427. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mori A, Moser C, Lang SA, et al:
Upregulation of Kruppel-like factor 5 in pancreatic cancer is
promoted by interleukin-1beta signaling and hypoxia-inducible
factor-1alpha. Mol Cancer Res. 7:1390–1398. 2009. View Article : Google Scholar : PubMed/NCBI
|
